Adaptimmune shareholders approve all proposals at AGM; adopt annual say-on-pay frequency

Adaptimmune Therapeutics PLC

All 13 resolutions passed, including re-election of directors Behbahani, Furey, Rawcliffe.
KPMG reappointed as auditor; Audit Committee authorized to set 2025 remuneration.
2025 Employee and Non-Employee Share Option Schemes approved.
Advisory vote on exec compensation frequency set to every 1 year; board to hold annual votes until 2031.
No dividend recommended for FY 2024; UK statutory accounts adopted.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.